MDT Medtronic plc

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.

Medtronic (NYSE:MDT) received FDA 510(k) clearance for its LigaSure RAS Maryland jaw device for the Hugo robotic-assisted surgery system in the U.S. The LigaSure RAS Maryland jaw brings Medtronic's established vessel sealing technology into Hugo procedures for general, gynecologic and urologic surgery settings. This authorization broadens the portfolio of energy instruments available on Hugo, giving hospitals another option as they evaluate robotic surgery platforms. The LigaSure RAS...

BSX's MedSurg segment supports growth, with Endoscopy and Neuromodulation gains offsetting Urology challenges and portfolio gaps.

SHCD is missing some of the healthiest dividend stocks.

In the closing of the recent trading day, Medtronic (MDT) stood at $87.09, denoting a -2.69% move from the preceding trading day.

Look at the breakdown of Intuitive Surgical's revenue streams—Instruments and Accessories alone generate roughly 60% of the top line on a per-procedure basis. That tight link between surgery volume and cash flow explains why investors reacted so sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed. With recurring earnings visibility clouded, how much downside risk is the market actually pricing in.

These stocks have some extremely low valuations given their strong financials and promising growth prospects.

Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One has raised its dividend for 54 consecutive years and still trades at a rare discount.

A healthcare giant sent a torrent of cash back to its owners, but the real story is what that money did, and did not, buy for the stock.

Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.

Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is the giant, selling hospitals everything from hip and knee products to capital equipment. ResMed is a sleep device maker with less than a quarter of Stryker's revenue. Stryker costs 32.6 times its past year's earnings, against 21.9 times for ResMed. So does Stryker's reach justify that higher price? T

Gilead Sciences, Inc. (NASDAQ:GILD) and Medtronic plc (NYSE:MDT) both combine growing healthcare businesses with regular cash returns to shareholders, but the sources of that growth look very different. Gilead is being propelled by its dominant HIV portfolio, where several products are expanding rapidly. On the other hand, Medtronic’s growth is spread across a much broader […]

Pfizer Inc. (NYSE:PFE) and Medtronic plc (NYSE:MDT) are both trying to prove that years of portfolio investment can translate into more durable growth, but the two healthcare giants are entering very different stages of their turnarounds. Pfizer is rebuilding around newer medicines as COVID revenue declines and generic and biosimilar competition approaches. Medtronic, meanwhile, is […]

Medtronic plc’s (NYSE:MDT) investment thesis rests on accelerating growth across its key innovation platforms. CEO Geoff Martha noted ongoing strength in core segments such as Cranial and Spinal Technologies, Surgical, and Cardiac Rhythm Management. This comes along with encouraging momentum in high-growth opportunities such as Hugo robotic surgery, Symplicity, Altaviva, Affera, and Stealth AXiS. Read […]

The medical device giant grew its top line by a double-digit percentage in the first quarter of its fiscal 2027.

Medtronic (NYSE:MDT) agreed a US$700 million partnership with Cornerstone Robotics to distribute the Sentire surgical system globally. The Cornerstone deal expands Medtronic's presence in surgical robotics beyond its existing platforms into a new multi-country distribution arrangement. Medtronic also partnered with Sonus Microsystems on AI-powered wearable ultrasound technology for maternal health programs in Kenya. There is more to Medtronic than the Cornerstone and Sonus partnerships...

The Series D round is part of a surge in investment into BCI startups and brings Precision Neuroscience’s total funding to $430 million.

Medtronic PLC (NYSE:MDT) recently announced a total dividend of $0.72 per share with the ex-dividend date set for 2026-09-25, including $0.72 per share cash dividend payable on 2026-10-16. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Medtronic PLC's dividend performance and assess its sustainability.

On September 1, Medtronic plc (NYSE:MDT) announced a $700 million strategic partnership with Hong Kong-based Cornerstone Robotics, securing rights to distribute Cornerstone’s Sentire surgical system in select market-approved regions outside the U.S. Medtronic will co-distribute Sentire alongside its proprietary Hugo robotic-assisted surgery system across Europe, China, and Singapore. The move allows Medtronic to offer tiered […]

Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. procedure growth. The more telling number is 144 trade-ins in fiscal Q2 2026, up from 83 a year earlier. Most came from customers moving to the new da Vinci 5 robot. Those trade-ins matter most if upgrades continue and each surgery also earns more. Is that number a blip, or are customers still trading up.

A bond coupon that felt safe a decade ago may be quietly bleeding your retirement dry, and Dave Ramsey's hurdle-rate math explains exactly why. The question is which assets can actually climb that bar year after year.

Medtronic (MDT) reached $89.3 at the closing of the latest trading day, reflecting a -1.62% change compared to its last close.

Medtronic plc (NYSE:MDT) drew a broad round of price-target increases after its fiscal 2027 first-quarter results, but Wall Street remains divided over whether accelerating growth can support a meaningful re-rating of the stock. The acceleration follows an earlier debate over whether Medtronic (MDT) is finally becoming a turnaround story. Bull Case: Growth Is Broadening Mizuho […]

Rising global concern around AI safety at the Trump Xi summit puts a spotlight on where artificial intelligence is already deeply embedded in real-world decisions. Few areas are as critical as healthcare. That is where algorithms do not just optimise ads, they help doctors interpret scans, triage patients, and support drug discovery. This article highlights three stocks from our transformative AI healthcare screener that capture that shift. The three stocks below are a small sample of what is...

Wall Street doesn't appear to be giving Medtronic credit for its improving results.

Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.

Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.

Markets are wrestling with a Fed that sounds more willing to tolerate economic pain than investors expected, while supply shocks from oil and tariffs keep pressure on costs. That mix tends to push attention toward reliable cash flows and dividends, as many traders reassess how much risk they really want to hold. This article walks through three large-cap, income-focused stocks exposed to this macro backdrop and explains how each may factor into your portfolio decisions now. The stocks below...

Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. That looks like a surgical-robot leader on sale, but the price history disagrees. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.

Medtronic (NYSE:MDT) received FDA clearance for its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. The authorization allows LigaSure to be used on the Hugo platform for soft-tissue procedures in U.S. hospitals and surgical centers. The cleared configuration integrates a widely used vessel-sealing tool with Medtronic’s robotic-assisted surgery platform for general surgery use. The new FDA clearance for LigaSure on Hugo is one more factor to weigh alongside the...

Healthcare services and products company Cardinal Health (NYSE:CAH)’s shares are up by more than 10% year-to-date but are down by more than 8% since early September. Cramer discussed the firm’s share price performance in his morning appearance on September 15th and wondered whether the weakness was due to a rotation into AI stocks rather than […]

They have a knack for increasing their dividends even when facing challenges.

Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry STELARA, which is losing share to biosimilar competition. What looks dear on earnings already reported comes down sharply on the earnings analysts expect.

Intuitive Surgical (ISRG) has lost about 12% over the past year, while the S&P 500 returned about 17%. Most of the debate has been about the U.S. procedure growth slowing. The number that should worry a holder more is the money the company collects on the instruments used in each operation. Intuitive plans to lower it.

The company is in the process of expanding the uses for its Hugo Surgical System and expanding its revenue base.

Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high. Even so, you pay about 35.9 times trailing adjusted earnings. That is normalized net income with stock-based compensation added back, a basis meant to sit closer to the one analysts forecast on, though the two are not defined identically. Analysts' forecasts run to 2027, the year Intuitive plans to start lowering what customers pay per use on some instruments.

Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.

Reuters reported that Medtronic plc (NYSE:MDT) raised the lower end of its fiscal 2027 profit forecast and its revenue growth outlook on September 1, banking on strong demand for heart devices used in complex cardiovascular procedures. The Ireland-based company raised the lower end of its adjusted per-share profit forecast to $5.94 from $5.90, keeping the […]

Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.

Widely adopted in open and laparoscopic surgeries, the LigaSure instrument is now available for use with the Hugo robotic system.

Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500. The change worth noticing over that stretch is quieter than the price. Management said sales still rose 5.6% despite a STELARA drag of about 460 basis points. Management is encouraging investors to evaluate the company's underlying momentum by presenting growth rates that exclude STELARA alongside its reported figures.

Barghout, who led Recor when it won FDA approval of the first renal denervation treatment for hypertension, is the new president of Medtronic’s Interventional Cardiology Therapies business.

In September 2026, Sonus Microsystems Inc. announced a collaboration with Medtronic plc to integrate its AI-powered Sonus Patch wearable ultrasound platform with Medtronic’s Acute Care & Monitoring technology, testing a non-invasive system in Kenya to screen and triage pregnant women at risk of early-onset preeclampsia under a Gates Foundation-funded study. This project not only expands Medtronic’s use of AI and remote monitoring, but also shows how its technology can be adapted for...

Medtronic (NYSE:MDT) Chief Financial Officer Thierry Piéton said the medical-device maker’s focus on acute procedures, expanding innovation pipeline and increased use of targeted acquisitions are supporting its recent growth momentum. Speaking with Peter Harrison of Morgan Stanley Investment Bankin

Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their 8.6 high.

BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.

Intuitive Surgical (ISRG) trades near $370, about 38% below its 52-week high, after growth in its US robotic-surgery procedures slowed. Selling a put pays you now for agreeing to buy the shares much lower, and you keep the payment either way. The catch is it only works if you would want this business at that price.

The separation will allow Medtronic to focus on its cardiovascular, neuroscience and surgical portfolios, CEO Geoff Martha said.

Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons admit, and the tiebreaker comes down to a single question about your timeline.